FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2334672625> ?p ?o ?g. }

• W2334672625 abstract "Event Abstract Back to Event In vitro screening of peptides and glycopeptides inhibitors of angiotensin I-converting enzyme Bozhidarka Pandova1*, Viliana Todorova1, Boriana Yakimova2, Stanislav Yanev1, Ivanka Stoineva2 and Bozhidar Chorbanov2 1 Institute of Neurobiology, Dept.Drug Toxicology, Bulgaria 2 Bulgarian Academy of Sciences, Institute of Organic Chemistry with Center of Phytochemistry, Bulgaria Introduction. Angiotensin I-converting enzyme (ACE) is a zinc-containing metalloprotein. It releases dipeptides from the C-terminus of the peptide substrates as angiotensin I and bradykinin leading to the synthesis of angiotensin II and breakdown of bradykinin thus inducing vasoconstriction. ACE inhibitors are among the most powerful drugs for regulation of blood pressure. In the present communication, the first results of in vitro testing of some peptides and glycopeptides inhibitors of ACE are presented. Materials and methods. An original method was applied for ACE activity determination. Rabbit serum was used as enzyme source. Serum aliquot was incubated in buffered medium with the ACE substrate analogue Hippuryl-Histidyl-Leucine (HHL). The hippuric acid produced is extracted and quantified relative to an internal standard by High Performance Liquid Chromatography (HPLC). The amount of hippuric acid formed reflects the ACE activity. Tree different proline peptides derivatives, two tree- and tetra- peptides derivatives and two aminocarbohydrates were tested for their inhibitory potency compared with the well known ACE inhibitors: Lisinopril (pyrrolidine derivative which is not metabolized and excreted unchanged in the urine) and Fosinoprilat (active metabolite of fosinopril, an pyrrolidine derivative). The IC50 and IC100 values were determined by non-linear regression analysis of enzyme activity/inhibitor concentrations curves using software package GraphPad Prism 5.0. Results.From the six compounds studied, the highest inhibitory potency possessed Val-Pro-Pro-OH with IC50 around 26 µM, followed by CF3-COOH-Val-Pro-Pro-Pro (IC50 around 0.51 mM), and HCl.Val-Pro-OH (IC50 around 0.9 mM). HCl.Suc-Val-OH, HCl-Glu-Val-OH and Suc-Boc-Val were ineffective up to 1 mM concentration. The inhibitory effect of Lisinopril and Fosinoprilat is much greater than that of Val-Pro-Pro-OH. The enzyme activity is 100% inhibited after 40 nM. Conclusion. The significant inhibition of ACE activity by some peptides derivatives is a good base for the synthesis of new compounds with greater inhibitory potency. Keywords: Angiotensin I-converting enzyme, ACE inhibitors Conference: 8th Southeast European Congress on Xenobiotic Metabolism and Toxicity - XEMET 2010, Thessaloniki, Greece, 1 Oct - 5 Oct, 2010. Presentation Type: Poster Topic: Xenobiotic toxicity Citation: Pandova B, Todorova V, Yakimova B, Yanev S, Stoineva I and Chorbanov B (2010). In vitro screening of peptides and glycopeptides inhibitors of angiotensin I-converting enzyme. Front. Pharmacol. Conference Abstract: 8th Southeast European Congress on Xenobiotic Metabolism and Toxicity - XEMET 2010. doi: 10.3389/conf.fphar.2010.60.00171 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 28 Oct 2010; Published Online: 04 Nov 2010. * Correspondence: Dr. Bozhidarka Pandova, Institute of Neurobiology, Dept.Drug Toxicology, Sofia, Bulgaria, stanislav_yanev@yahoo.com Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Bozhidarka Pandova Viliana Todorova Boriana Yakimova Stanislav Yanev Ivanka Stoineva Bozhidar Chorbanov Google Bozhidarka Pandova Viliana Todorova Boriana Yakimova Stanislav Yanev Ivanka Stoineva Bozhidar Chorbanov Google Scholar Bozhidarka Pandova Viliana Todorova Boriana Yakimova Stanislav Yanev Ivanka Stoineva Bozhidar Chorbanov PubMed Bozhidarka Pandova Viliana Todorova Boriana Yakimova Stanislav Yanev Ivanka Stoineva Bozhidar Chorbanov Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page." @default.
• W2334672625 created "2016-06-24" @default.
• W2334672625 creator A5036349554 @default.
• W2334672625 date "2010-01-01" @default.
• W2334672625 modified "2023-09-26" @default.
• W2334672625 title "In vitro screening of peptides and glycopeptides inhibitors of angiotensin I-converting enzyme" @default.
• W2334672625 doi "https://doi.org/10.3389/conf.fphar.2010.60.00171" @default.
• W2334672625 hasPublicationYear "2010" @default.
• W2334672625 type Work @default.
• W2334672625 sameAs 2334672625 @default.
• W2334672625 citedByCount "0" @default.
• W2334672625 crossrefType "journal-article" @default.
• W2334672625 hasAuthorship W2334672625A5036349554 @default.
• W2334672625 hasBestOaLocation W23346726251 @default.
• W2334672625 hasConcept C126322002 @default.
• W2334672625 hasConcept C170493617 @default.
• W2334672625 hasConcept C181199279 @default.
• W2334672625 hasConcept C185592680 @default.
• W2334672625 hasConcept C27016395 @default.
• W2334672625 hasConcept C2779591629 @default.
• W2334672625 hasConcept C2780026642 @default.
• W2334672625 hasConcept C2780548424 @default.
• W2334672625 hasConcept C2908929049 @default.
• W2334672625 hasConcept C55493867 @default.
• W2334672625 hasConcept C71924100 @default.
• W2334672625 hasConcept C84393581 @default.
• W2334672625 hasConcept C98274493 @default.
• W2334672625 hasConceptScore W2334672625C126322002 @default.
• W2334672625 hasConceptScore W2334672625C170493617 @default.
• W2334672625 hasConceptScore W2334672625C181199279 @default.
• W2334672625 hasConceptScore W2334672625C185592680 @default.
• W2334672625 hasConceptScore W2334672625C27016395 @default.
• W2334672625 hasConceptScore W2334672625C2779591629 @default.
• W2334672625 hasConceptScore W2334672625C2780026642 @default.
• W2334672625 hasConceptScore W2334672625C2780548424 @default.
• W2334672625 hasConceptScore W2334672625C2908929049 @default.
• W2334672625 hasConceptScore W2334672625C55493867 @default.
• W2334672625 hasConceptScore W2334672625C71924100 @default.
• W2334672625 hasConceptScore W2334672625C84393581 @default.
• W2334672625 hasConceptScore W2334672625C98274493 @default.
• W2334672625 hasLocation W23346726251 @default.
• W2334672625 hasOpenAccess W2334672625 @default.
• W2334672625 hasPrimaryLocation W23346726251 @default.
• W2334672625 hasRelatedWork W1976408724 @default.
• W2334672625 hasRelatedWork W1984346054 @default.
• W2334672625 hasRelatedWork W1998263215 @default.
• W2334672625 hasRelatedWork W1998265077 @default.
• W2334672625 hasRelatedWork W2061162449 @default.
• W2334672625 hasRelatedWork W2153891065 @default.
• W2334672625 hasRelatedWork W2397361688 @default.
• W2334672625 hasRelatedWork W2411973909 @default.
• W2334672625 hasRelatedWork W2417665051 @default.
• W2334672625 hasRelatedWork W2118665693 @default.
• W2334672625 hasVolume "1" @default.
• W2334672625 isParatext "false" @default.
• W2334672625 isRetracted "false" @default.
• W2334672625 magId "2334672625" @default.
• W2334672625 workType "article" @default.